NeOnc is a privately held biotechnology company focused on creating novel drugs and delivery methods for pharma-based therapeutics that target brain and central nervous system diseases. The company's NEO 100 is its first therapeutic that completed Phase One clinical trials in April 2019. It is also developing several proprietary chemotherapy agents that have demonstrated positive effects in laboratory tests on various types of cancers. As the result of its extensive research and development efforts, the company has assembled an extensive portfolio of patented intellectual property around these proprietary chemotherapy agents.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/08/23 | $10,000,000 |
Eminent II Venture Capital Lin Family Office Orion BioScience | $70,000,000 |
